Clinical Trial Update: A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma. [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating tislelizumab in combination with cisplatin and gemcitabine, with or without trilaciclib, for untreated unresectable and metastatic ur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Tislelizumab (tislelizumab)
• trilaciclib (trilaciclib)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Bladder Cancer | Phase 3 | Status: NOT_YET_RECRUITING